Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Allergan announces takeover of Anterios

Allergan announces takeover of Anterios

14th January 2016

Allergan has agreed a deal to purchase Anterios, a clinical-stage biopharmaceutical company developing a next-generation delivery system and botulinum toxin-based prescription products.

The medical dermatology and aesthetic medicine company has been acquired to help expand Allergan's neurotoxin pipeline, with the firm paying an upfront fee of $90 million (62.62 million pounds), in addition to milestone-based payments.

Anterios' portfolio includes NDS, a proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without the need for injections, as well as ANT-1207, an investigational topical treatment for hyperhidrosis, acne and crow's feet lines.

David Nicholson, executive vice-president and president of global brands research and development at Allergan, said: "This acquisition demonstrates our ability to apply our tremendous scientific leadership in neurotoxins to further extend our already deep neurotoxin pipeline by advancing a new delivery system and formulations that are appealing to both patients and physicians."

It was recently announced that Allergan will soon be merging with Pfizer as part of a $160 billion deal, the biggest transaction in pharmaceutical industry history.ADNFCR-8000103-ID-801810022-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.